- | GigaGen
Episode 20-28 Antibodies, Antibodies, the More, the Better.
What if we could just get the antibodies from all the various strains of COVID-19, put them together and get them in an IV drug? Well, that’s exactly what Gigagen has done. Today, when Moira speaks with geneticist David Johnson, its co-founder, President and CEO of Gigagen.
- | Recce Pharmaceuticals
New Class of Synthetic Polymer-Antibiotics Overcomes Antibiotic Resistance with Michele Dilizia Recce Pharmaceuticals
Michele Dilizia, Executive Director of Regulatory Affairs and Microbiology, Recce Pharmaceuticals discusses why Recce is focused on developing a new class of broad spectrum synthetic polymer-antibiotics that can be used repeatedly against a wide range of bacteria without contributing to antibiotic resistance. Michele also speaks to how Recce® 327, Recce’s lead asset, is designed to empower doctors with a near universal treatment that can kill multiple types of bacteria in the blood, even superbugs, that can cause sepsis.
- | Recce Pharmaceuticals
Applying A Synthetic Approach To The Development Of A New Generation Of Antibiotics
Australian company Recce Pharmaceuticals (ASX: RCE) is advancing a synthetic polymer antibiotic designed with optimum properties that exhibits high potency against a broad range of bacteria.
- | DURECT
Epigenetic Regulation To Treat Acute Organ Injury And Chronic Liver Diseases
DURECT Corporation is advancing an epigenetic regulator program aimed at developing products to treat acute AH and nonalcoholic steatohepatitis (NASH), a type of nonalcoholic fatty liver disease. DURECT’s therapeutics in development have the potential to treat multiple organ injury and chronic liver diseases.
- | Heat Bio
Jeff Wolf: Congress and the administration: Seniors and certain minority groups need a ‘super-vaccine’
The critical difference is that older patients and those who are immune-compromised tend to lack a robust T-cell response, which Heat Biologics believes is important in preventing the disease. With the typical flu, seniors are often prescribed a double-dose of vaccine to compensate for their inability to mount an effective adaptive response. This approach, however, may not be optimal in vaccinating against COVID-19. New data suggests that a combination of T-cell and antibody responses against COVID-19 may provide the best protection for seniors and others.
- | 9 Meters
Assembling a Pipeline for Rare GI Disorders
9 Meters Biopharma is focused on rare gastrointestinal conditions. It is advancing an experimental therapy for short bowel syndrome. We spoke to John Temperato, president and CEO of 9 Meters Biophama, about short bowel syndrome, the company’s experimental therapy to treat the condition, and how the company has built its pipeline through two recent mergers.
- | Aligos Therapeutics
Aligos Therapeutics — The Next Step Of Lawrence Blatt’s Entrepreneurial Expedition
Not long ago, someone asked Lawrence Blatt, Ph.D., the probability that one of his company’s drugs would be successful. “I don’t want to think about that,” responded the CEO of Aligos Therapeutics. Blatt wasn’t trying to be coy; he knew the answer, and he knew it wouldn’t sound good.
- | Chiasma
Chiasma secures FDA approval for acromegaly pill Mycapssa years after near-catastrophic rejection
Chiasma’s Mycapssa (octreotide) has become the first FDA-approved oral therapy to treat acromegaly, a rare disorder in which overproduction of human growth hormone leads to abnormal enlargement of patients’ extremities and internal organs, the drugmaker said.
